Romidepsin

Small molecule

Also known as FK228

Approvedregulatory verdict

Evidence outlook

Approved: Cutaneous T-Cell Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
JP
  • Treatment of relapsed or refractory peripheral T- cell lymphoma
Product first approved 2017PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Other / comorbidity
NCT01796002 · The Lymphoma Academic Research Organisation
2013-01 – 2022-12-13 · Peripheral T-cell Lymphoma
What this study did
NCT03355768 · Jennifer Amengual
2018-09-01 – 2018-11-01 · Lymphoma, T-Cell, Peripheral
What this study did
Phase 2 (35)
Cutaneous T-Cell Lymphoma
NCT02232516 · Northwestern University
2015-06-11 – 2024-03-16 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
What this study did
Other / comorbidity
NCT04747236 · University of Virginia
2021-02-19 – 2030-06-02 · PTCL
What this study did
NCT01908777 · Memorial Sloan Kettering Cancer Center
2013-07-16 – 2025-10-03 · T Cell Non-Hodgkin Lymphoma
What this study did
NCT03534180 · City of Hope Medical Center
2018-09-11 – 2023-07-26 · Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
What this study did
NCT03041012 · Aarhus University Hospital
2017-01-20 – 2022-12-30 · Hiv
What this study did
NCT02850016 · Rockefeller University
2017-01-06 – 2020-12-31 · Human Immunodeficiency Virus (HIV)
What this study did
NCT01822886 · Fondazione Italiana Linfomi - ETS
2013-01 – 2018-07 · Peripheral T-cell Lymphoma
What this study did
NCT00426764 · Celgene
2007-06-19 – 2018-05-17 · Peripheral T-cell Lymphoma
What this study did
NCT01353664 · Celgene
2011-05-01 – 2012-09-05 · Lymphoma, Cancer
What this study did
NCT00084682 · National Cancer Institute (NCI)
2005-06 – 2012-03 · Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
What this study did
NCT00383565 · National Cancer Institute (NCI)
2006-09 – 2011-04 · Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
What this study did
NCT00066638 · National Cancer Institute (NCI)
2003-06 – 2011-03 · DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT00765102 · Celgene
2008-09-01 – 2010-03-01 · Multiple Myeloma
What this study did
NCT00098813 · National Cancer Institute (NCI)
2004-10 – 2009-08 · Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
What this study did
NCT00104884 · ECOG-ACRIN Cancer Research Group
2005-10-04 – 2009-03 · Malignant Melanoma, Melanoma
What this study did
NCT00112463 · National Cancer Institute (NCI)
2005-01-07 – 2008-10-23 · Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
What this study did
NCT00020202 · National Cancer Institute (NCI)
2000-06 – 2007-03 · Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
What this study did
NCT00091195 · National Cancer Institute (NCI)
2004-09 – 2007-03 · Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
What this study did
NCT00062075 · National Cancer Institute (NCI)
2003-05 – 2007-03 · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
What this study did
NCT00086827 · National Cancer Institute (NCI)
2004-05 – 2006-11 · Recurrent Small Cell Lung Cancer
What this study did
NCT00106418 · Celgene
2003-05-07 – 2006-09-01 · Prostate Cancer, Metastases
What this study did
NCT00106301 · Celgene
2004-04-01 – 2006-09-01 · Carcinoma, Renal Cell, Prostatic Neoplasms
What this study did
NCT00077337 · SWOG Cancer Research Network
2004-04 – 2006-04 · Colorectal Cancer
What this study did
NCT00087295 · SWOG Cancer Research Network
2004-06 – 2006-04 · Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
What this study did
NCT00077194 · National Cancer Institute (NCI)
2004-01 – 2005-12 · Lymphoma
What this study did
NCT00085527 · University of Chicago
2005-05 – 2005-09 · Ovarian Cancer
What this study did
NCT00098527 · National Cancer Institute (NCI)
2004-10 – 2005-09 · Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
What this study did
NCT00079443 · National Cancer Institute (NCI)
2004-01 – 2005-09 · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
What this study did
NCT00098397 · National Cancer Institute (NCI)
2005-02 – 2005-09 · Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00042822 · Memorial Sloan Kettering Cancer Center
2002-05 – 2005-03 · Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
What this study did
NCT00084461 · National Cancer Institute (NCI)
2004-03 – 2004-10 · Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Regional Gastrointestinal Carcinoid Tumor, Somatostatinoma
What this study did
NCT00106613 · Celgene
2003-05-01 – 2004-08-01 · Carcinoma, Renal Cell, Neoplasm Metastasis
What this study did
Phase 1/2 (20)
Cutaneous T-Cell Lymphoma
NCT03278782 · M.D. Anderson Cancer Center
2017-11-14 – 2026-10-09 · Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
What this study did
Other / comorbidity
NCT02393794 · Priyanka Sharma
2015-07-17 – 2026-07 · Triple-Negative Breast Cancer, Breast Cancer
What this study did
NCT04257448 · GWT-TUD GmbH
2020-05-25 – 2024-07-02 · Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
What this study did
NCT01755975 · Memorial Sloan Kettering Cancer Center
2012-12 – 2023-10 · Multiple Myeloma, Non-Hodgkin's Lymphoma
What this study did
NCT03161223 · University of Virginia
2018-05-30 – 2023-02 · Lymphoma, T-Cell
What this study did
NCT02341014 · Memorial Sloan Kettering Cancer Center
2015-01-02 – 2023-01-11 · T-cell Lymphomas, Relapsed or Refractory
What this study did
NCT01947140 · Jennifer Amengual
2013-09-09 – 2022-09-01 · Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
What this study did
NCT03141203 · University of Birmingham
2015-07-13 – 2021-09-23 · Peripheral T Cell Lymphoma
What this study did
NCT03770000 · Rhizen Pharmaceuticals SA
2019-03-12 – 2021-05-14 · T Cell Lymphoma
What this study did
NCT02281279 · Mayo Clinic
2016-10 – 2020-10 · B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT03547700 · University of Michigan Rogel Cancer Center
2018-09-26 – 2020-08-27 · Lymphoma, T-Cell, Peripheral
What this study did
NCT01998035 · Columbia University
2013-11 – 2020-01-06 · Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
What this study did
NCT01456039 · Celgene
2011-12-01 – 2018-12-14 · Lymphoma, T-cell, Peripheral
What this study did
NCT01933594 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-05-05 – 2018-04-16 · HIV Infections
What this study did
NCT01938833 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2014-04 – 2016-12-08 · HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01979276 · Weill Medical College of Cornell University
2013-11 – 2016-10 · Multiple Myeloma
What this study did
NCT02092116 · Bionor Immuno AS
2014-03 – 2015-12 · HIV I Infection
What this study did
NCT01280526 · The Lymphoma Academic Research Organisation
2011-01 – 2014-03 · Peripheral T Cell Lymphoma
What this study did
NCT00431990 · Peter MacCallum Cancer Centre, Australia
2006-11 – 2012-01 · Multiple Myeloma
What this study did
NCT00085540 · National Cancer Institute (NCI)
2005-01 – 2009-03 · Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
What this study did
Phase 1 (37)
Cutaneous T-Cell Lymphoma
NCT04447027 · National Cancer Institute (NCI)
2020-12-17 – 2025-12-17 · Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
What this study did
NCT02512497 · Ohio State University Comprehensive Cancer Center
2017-12-08 – 2025-06-18 · Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
What this study did
NCT04774068 · Walter Hanel
2021-09-01 – 2024-10-27 · Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Mycosis Fungoides, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Mycosis Fungoides, T-Cell Non-Hodgkin Lymphoma
What this study did
NCT02616965 · Fox Chase Cancer Center
2017-02-22 – 2024-01-31 · Cutaneous T-cell Lymphoma (CTCL)
What this study did
NCT03432741 · Mayo Clinic
2018-03-27 – 2022-10-03 · Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02181218 · Washington University School of Medicine
2015-02-04 – 2020-06-26 · Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
What this study did
NCT01902225 · Weiyun Ai
2014-03-04 – 2020-04-11 · Lymphoma, T-Cell Lymphoma, Cutaneous Lymphoma
What this study did
NCT02061449 · NYU Langone Health
2014-03 – 2018-11-05 · Cutaneous T-cell Lymphoma
What this study did
NCT01590732 · M.D. Anderson Cancer Center
2012-10-29 – 2018-05-02 · Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
What this study did
NCT01738594 · Northwestern University
2013-03-22 – 2016-10-11 · Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
What this study did
NCT01445340 · National Cancer Institute (NCI)
2007-04-21 – 2012-06-29 · Mycosis Fungoides, Cutaneous T-Cell Lymphoma, Neoplasms
What this study did
Other / comorbidity
NCT06963346 · H. Lee Moffitt Cancer Center and Research Institute
2025-06-24 – 2028-04 · Bladder Cancer
What this study did
NCT02783625 · Memorial Sloan Kettering Cancer Center
2016-05-23 – 2026-04-21 · Lymphoma, Relapsed/Refractory T-cell Lymphomas
What this study did
NCT05230368 · ANRS, Emerging Infectious Diseases
2022-12-14 – 2025-12-11 · HIV-1-infection, Subtype b
What this study did
NCT04233697 · Columbia University
2020-02 – 2023-07-30 · Lymphoma, T-Cell
What this study did
NCT04639843 · National Cancer Institute (NCI)
2022-11-03 – 2022-11-03 · Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma, Hepatosplenic T-cell Lymphoma
What this study did
NCT02512172 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-02-19 – 2021-11-20 · Colorectal Cancer
What this study did
NCT01638533 · National Cancer Institute (NCI)
2012-08-03 – 2020-09-01 · Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
What this study did
NCT01897012 · National Cancer Institute (NCI)
2013-07-17 – 2018-11-30 · MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
What this study did
NCT01846390 · Canadian Cancer Trials Group
2013-10-01 – 2018-09-19 · Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
What this study did
NCT00963274 · Virginia Commonwealth University
2010-04-26 – 2018-04-13 · Leukemia, Lymphoma
What this study did
NCT02757248 · Anne Beaven, MD
2016-11 – 2016-11 · PTCL, CTCL
What this study did
NCT01537744 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012-02 – 2016-09 · Solid Tumors, Virally Mediated Cancers and Liposarcoma
What this study did
NCT01742793 · Yale University
2012-10 – 2016-08 · Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
What this study did
NCT00019318 · National Cancer Institute (NCI)
started 1997-08 · Lymphoma
What this study did
NCT01302808 · University of Texas Southwestern Medical Center
2009-09 – 2014-12 · Lung Cancer, Metastatic Cancer
What this study did
NCT01913119 · Samsung Medical Center
2013-07 – 2013-07 · Histologically Proven Extranodal NKTcell Lymphoma
What this study did
NCT00094978 · National Cancer Institute (NCI)
2004-10-25 – 2013-05-20 · Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Mesothelioma
What this study did
NCT01324323 · Celgene
2011-04-01 – 2012-03-01 · Hematologic Malignancy, Malignant Lymphoma
What this study did
NCT01324310 · Celgene
2011-04-01 – 2012-01-01 · Hematologic Malignancy, Malignant Lymphoma
What this study did
NCT00048334 · National Cancer Institute (NCI)
2002-10-26 – 2010-04-01 · Neoplasms
What this study did
NCT00037817 · National Cancer Institute (NCI)
2002-05-17 – 2009-11-09 · Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
What this study did
NCT00379639 · Celgene
2006-07-01 – 2008-07-01 · Pancreatic Cancer
What this study did
NCT00114257 · National Cancer Institute (NCI)
2005-05 – 2006-09 · Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
What this study did
NCT00024180 · Ohio State University Comprehensive Cancer Center
2002-01 – 2006-08 · Leukemia, Lymphoma
What this study did
NCT00053963 · National Cancer Institute (NCI)
2002-09 – 2006-02 · Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02203578 · Rutgers, The State University of New Jersey
2014-11 – 2016-06-14 · Graft Versus Host Disease
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Other / comorbidity
NCT03593018 · The Lymphoma Academic Research Organisation
2018-11-09 – 2025-08-28 · Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma
What this study did
NCT01482962 · Millennium Pharmaceuticals, Inc.
2012-06-11 – 2017-12-18 · Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cutaneous T-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Romidepsin: this drugApprovedSmall moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatePartial signal
NCT01578499: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) (Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)): Brentuximab Vedotin 54.7 percentage of participants (95% CI 42.5 to 66.9) | Methotrexate or Bexarotene 12.5 percentage of participants (95% CI 4.4 to 20.6)
Givinostat
Approved(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
VorinostatApprovedSmall moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
Panobinostat
US approval withdrawn(overall)
Small moleculeHDAC
Partial signal(overall)
No reviewed efficacy summary in this indication
Chidamide
Phase 3(overall)
Small moleculeHDAC
Reliable signal(overall)
No reviewed efficacy summary in this indication
Purinostat Mesylate
Phase 3(overall)
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication
LacutamabPhase 2Monoclonal antibodyKIR3DL2not yet gradedNo reviewed efficacy summary in this indication
REC-2282
Discontinued
Small moleculeHDAC
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Romidepsin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
April 2028 (1)
Phase 1Bladder CancerRecruiting
Est. primary completion 2028-04 · NCT06963346 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2PTCLRecruiting
Est. primary completion 2028-06-02 · NCT04747236 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 June 2026ApprovalFDA approves Amneal romidepsin injection solution
US, FDA · Source ↗